Effective Novel Target
With high potency and specificity, our therapies deliver a strong therapeutic impact while maintaining low remission rates to maximize long-term disease control. Leveraging advanced target discovery approaches, we work to identify additional new targets to improve underserved treatment paradigms.
CR-Fc Platform
& Multiple Target Approach
Designed for rational combination therapies, our unique CR-Fc platform enhances treatment effectiveness by targeting multiple disease mechanisms. Our biologics feature extended half-lives, optimizing pharmacokinetics for sustained efficacy. Built on a distinctive platform, our drugs address multiple disease pathways and offer comprehensive and long-lasting treatment solutions.
Focused on Safety and Efficacy
Our biologic is designed to achieve precise immune modulation with a focus on minimizing infection risk. Early data from human PBMC studies suggest low immunogenicity, with low anti-drug antibody (ADA) levels observed in comparative evaluation. In addition, ongoing candida studies suggest the potential for a more favorable safety profile in terms of infection risk compared to existing commercial therapies, while maintaining comparable efficacy.
Convenient Administration
Our small molecule drugs are developed as oral formulations to enable seamless combination with other treatments and to enhance patient compliance.
Our biologics are developed as subcutaneous injection for long-term, sustained efficacy. New therapeutic candidates are continuously advanced to optimize treatment outcomes.
